

Regioselective Bromination of Fused Heterocyclic *N*-Oxides

Sarah E. Wengryniuk, Andreas Weickgenannt, Christopher Reiher, Neil Strotman, Ke Chen*, Martin D. Eastgate*, Phil S. Baran*

Department of Chemistry and Chemical Biology, The Scripps Research Institute, 10550

North Torrey Pines Road, San Diego, CA 92037, USA

Chemical Development, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, New Jersey, 08903, United States

Supporting Information

Table of Contents

General Experimental	SI-2
General Procedure I: Oxidation of azines	SI-3
3-Methoxyquinoline <i>N</i>-oxide (11)	SI-3
4-Methoxyquinoline <i>N</i>-oxide (SI-1)	SI-4
5-Methoxyquinoline <i>N</i>-oxide (SI-2)	SI-4
8-Methoxyquinoline <i>N</i>-oxide (SI-3)	SI-4
6-Fluoroquinoline <i>N</i>-oxide (10)	SI-5
6-Chloroquinoline <i>N</i>-oxide (SI-4)	SI-5
6-Bromoquinoline <i>N</i>-oxide (SI-5)	SI-6
4-Methoxyisoquinoline <i>N</i>-oxide (SI-6)	SI-6
5-Methoxyisoquinoline <i>N</i>-oxide (SI-7)	SI-6
4-Fluoroisoquinoline <i>N</i>-oxide (SI-8)	SI-7
4-Chloroisoquinoline <i>N</i>-oxide (SI-9)	SI-7
6-Acetyl-5-bromofuro[3,2-<i>b</i>]pyridine 4-oxide (SI-10)	SI-8
<i>N</i>1-1,10-phenanthroline <i>N</i>-oxide (SI-11)	SI-8
Quinine <i>N</i>-oxide (SI-12)	SI-8
General Procedure II: Protection and oxidation of azaindoles	SI-9

<i>N</i>1-benzenesulfonyl-4-methoxy-6-azainole <i>N</i>6-oxide (SI-13)	 SI-9
General Procedure III: Bromination of azine <i>N</i>-oxides	 SI-10
2-Bromo-6-methoxyquinoline (9)	 SI-12
2-Bromoquinoline (15)	 SI-10
2-Bromo-3-methoxyquinoline (16)	 SI-10
2-Bromo-4-methoxyquinoline (17)	 SI-11
2-Bromo-5-methoxyquinoline (18)	 SI-11
2-Bromo-8-methoxyquinoline (19)	 SI-12
2-Bromo-6-fluoroquinoline (20)	 SI-12
2-Bromo-6-chloroquinoline (21)	 SI-13
2,6-Dibromoquinoline (22)	 SI-13
1-Bromoisquinoline (23)	 SI-13
1-Bromo-4-methoxyisoquinoline (24)	 SI-14
1-Bromo-5-methoxyisoquinoline (25)	 SI-14
1-Bromo-4-fluoroisoquinoline (26)	 SI-15
1-Bromo-4-chloroisoquinoline (27)	 SI-15
7-Bromo-4-methoxy-1-(phenylsulfonyl)-1H-pyrrolo[2,3-<i>c</i>]pyridine (28)	 SI-15
1-(5-Bromofuro[3,2-<i>b</i>]pyridin-6-yl)ethanone (29)	 SI-16
2-Bromo-1,10-phenanthroline (30)	 SI-16
2-Bromo-quinine (31)	 SI-17
Chlorination of 6-methoxyquinoline <i>N</i>-oxide	 SI-17
2-Chloro-6-methoxyquinoline (14)	 SI-18
4-Chloro-6-methoxyquinoline (SI-14)	 SI-18
One-Pot Oxidation/Bromination Sequence	 SI-18
Table of Pyridine Derivatives Screened	 SI-19


General Experimental

All reactions were either carried out under air (oxidation of azines) or in flame-dried glassware under an atmosphere of argon (bromination of azine *N*-oxides). All reagents

were purchased at the highest commercial quality and used without further purification, except for of *p*-toluenesulfonic anhydride (recrystallized from benzene/Et₂O) and tetrabutylammonium bromide (recrystallized from benzene/hexanes). Starting materials including 6-methoxyquinoline *N*-oxide, quinolone *N*-oxide, 8-methoxyisoquinoline *N*-oxide, and isoquinoline *N*-oxide were purchased from commercial sources and used without further purification. Yields refer to chromatographically and spectroscopically pure material (¹H NMR, ¹³C NMR). Reactions were monitored by thin layer chromatography (TLC) carried out on 0.25 mm E. Merck silica plates (60F-254), using ultra violet light (UV) as the visualizing agent. Flash silica gel chromatography was performed using E. Merck silica gel (60, particle size 0.043-0.063 mm). Nuclear magnetic resonance spectra (NMR) were recorded on Bruker AV-400, DRX-500, and DRX-600 instruments and were calibrated using residual undeuterated solvent as an internal reference (¹H NMR: CHCl₃ 7.26 ppm, ¹³C NMR: CDCl₃ 77.16) or an internal instrument calibration for ¹⁹F. The following abbreviations were used to indicate multiplicities: *s* = singlet, *d* = doublet. High resolution mass spectra (HRMS) were recorded on an Agilent LC/MSD TOF mass spectrometer by electrospray ionization time of flight reflectron experiments. Infrared spectra (IR) were recorded on a Perkin Elmer Spectrum BX FTIR spectrometer. Melting points were recorded on a Fisher-Johns 12-144 melting point apparatus and are uncorrected.


General Procedure I: Oxidation of azines

To a 0 °C solution of the appropriate azine in CH₂Cl₂ (0.5M) is added *m*CPBA (2.0 equiv) and the reaction is allowed to stir at room temperature overnight. The reaction mixture is diluted with CH₂Cl₂ and washed with aq. KOH (6N, 3x), the organic layer is dried over Na₂SO₄ and the solvent is evaporated under reduced pressure. The azine *N*-oxides are obtained as white solids and used without further purification unless stated otherwise.




3-Methoxyquinoline *N*-oxide (11)

Using 3-methoxyquinoline in accordance with General Procedure I, the title compound was obtained (76% yield) as an off-white solid. **Mp**: 55 °C (CH₂Cl₂); **IR** (neat): ν_{max} 2362, 2340, 1593, 1470, 1385, 1346, 1211, 1141, 1085, 671, 655 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.67 – 8.57 (m, 1H), 8.37 (d, *J* = 2.2 Hz, 1H), 7.80 – 7.67 (m, 1H), 7.64 – 7.52 (m, 2H), 7.10 (d, *J* = 2.3 Hz, 1H), 3.95 (d, *J* = 1.3 Hz, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 153.6, 137.8, 130.2, 129.8, 129.4, 127.8, 127.3, 119.8, 105.4, 56.2; **HRMS** (ESI-TOF) calcd for C₉H₉NO₂H⁺ [(M+H)⁺] 176.0706, found 176.0709.




4-Methoxyquinoline *N*-oxide (SI-1)

Using 4-methoxyquinoline in accordance with General Procedure I, the title compound was obtained (41% yield) as a red solid. **Mp**: 39 °C; **IR** (neat): ν_{max} 2361, 2339, 2598, 1573, 1462, 1394, 1323, 1284, 1210, 1194, 11168, 1095, 968, 752 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.64 (d, *J* = 8.8 Hz, 1H), 8.38 (d, *J* = 6.8 Hz, 1H), 8.12 (d, *J* = 8.5 Hz, 1H), 7.71 (ddd, *J* = 8.3, 6.8, 1.2 Hz, 1H), 7.55 (dd, *J* = 7.6, 7.6 Hz, 1H), 6.54 (d, *J* = 6.8 Hz, 1H), 3.96 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 154.8, 141.2, 136.3, 131.1, 128.4, 128.1, 122.7, 119.9, 99.6, 56.4; **HRMS** (ESI-TOF) calcd for C₁₀H₉NO₂⁺ [(M+H)⁺] 176.0706, found 176.0703.




5-Methoxyquinoline *N*-oxide (SI-2)

Using 5-methoxyquinoline in accordance with General Procedure I, the title compound was obtained (80% yield) as an off-white solid. **Mp**: 74–76 °C (CH₂Cl₂); **R_f** = 0.27 (CH₂Cl₂:MeOH 20:1); **IR** (neat): $\nu_{\max}$ 2361, 2240, 1553, 1403, 1377, 1268, 1208, 1044, 779, 671 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 8.53 (d, *J* = 4.6 Hz, 1H), 8.30 (d, *J* = 8.8 Hz, 1H), 8.13 (d, *J* = 8.7 Hz, 1H), 7.66 (dd, *J* = 8.2, 8.2 Hz, 1H), 7.24 (m, 1H), 7.10 (dd, *J* = 7.8, 7.8 Hz, 1H), 4.12 (s, 3H) ppm; **¹³C NMR** (151 MHz, CDCl₃) δ 155.7, 142.5, 136.4, 130.8, 123.4, 121.3, 119.9, 111.7, 106.6, 56.2; **HRMS** (ESI-TOF) calcd for C₁₀H₉NO₂H⁺ [(M+H)⁺] 176.0706, found 176.0711.



8-Methoxyquinoline *N*-oxide (SI-3)


Using 8-methoxyquinoline in accordance with General Procedure I, the title compound was obtained (68% yield) as an off-white solid. **Mp**: 58 °C (CH₂Cl₂); **IR** (neat): $\nu_{\max}$ 2361, 2340, 1571, 1461, 1388, 1284, 1265, 1082, 813, 727, 699, 539 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.40 (dd, *J* = 6.1, 1.2 Hz, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.46 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.37 (d, *J* = 8.2 Hz, 1H), 7.18 (dd, *J* = 8.3, 6.2 Hz, 1H), 7.06 (d, *J* = 7.9 Hz, 1H), 4.01 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 153.8, 138.2, 134.3, 133.8, 128.8, 125.6, 121.4, 120.6, 111.0, 57.2; **HRMS** (ESI-TOF) calcd for C₁₀H₉NO₂H⁺ [(M+H)⁺] 176.0706, found 176.0714.



6-Fluoroquinoline *N*-oxide (10)


Using 6-fluoroquinoline in accordance with General Procedure I, the title compound was obtained (55% yield) as a white solid. **Mp**: 90 °C (CH₂Cl₂); **R_f** = 0.22 (CH₂Cl₂:MeOH 20:1);

IR (neat): $\nu_{\max}$ 2361, 2340, 1629, 1572, 1512, 1381, 1238, 1265, 1199, 1176, 850, 788, 731, 453 cm^{-1} ; **^1H NMR** (600 MHz, CDCl_3) δ 8.77 (dd, J = 9.3, 5.2 Hz, 1H), 8.48 (d, J = 6.0 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.53 – 7.47 (m, 2H), 7.32 (dd, J = 8.2, 6.5 Hz, 1H); **^{13}C NMR** (151 MHz, CDCl_3) δ 161.9, 138.9, 135.1, 131.8, 125.2, 123.1, 122.4, 120.5, 111.6 ; **^{19}F NMR** (376 MHz, CDCl_3) δ -110.6. **HRMS** (ESI-TOF) calcd for $\text{C}_9\text{H}_6\text{FNOH}^+$ [(M+H) $^+$] 164.0506, found 164.0508.



6-Chloroquinoline *N*-oxide (SI-4)


Using 6-chloroquinoline in accordance with General Procedure I, the title compound was obtained (93% yield) as a white solid. **Mp**: 108 °C (CH_2Cl_2); **R_f** = 0.25 (CH_2Cl_2 :MeOH 20:1); **IR** (neat): $\nu_{\max}$ 2360, 2340, 1561, 1503, 1441, 1424, 1359, 1301, 1264, 1222, 1175, 1141, 1095, 1073, 829, 791, 733, 579 cm^{-1} ; **^1H NMR** (500 MHz, CDCl_3) δ 8.71 (d, J = 9.3 Hz, 1H), 8.50 (d, J = 6.2 Hz, 1H), 7.87 (d, J = 2.2 Hz, 1H), 7.69 (dd, J = 9.3, 2.2 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.33 (dd, J = 8.5, 6.0 Hz, 1H); **^{13}C NMR** (151 MHz, CDCl_3) δ 140.3, 135.8, 135.2, 131.4, 131.3, 126.9, 124.8, 122.4, 121.9; **HRMS** (ESI-TOF) calcd for $\text{C}_9\text{H}_6\text{ClNOH}^+$ [(M+H) $^+$] 180.0211, found 180.0209.



6-Bromoquinoline *N*-oxide (SI-5)


Using 6-bromoquinoline in accordance with General Procedure I, the title compound was obtained (94% yield) as a white solid. **Mp**: 110 °C (CH_2Cl_2); **R_f** = 0.22 (CH_2Cl_2 :MeOH 20:1); **IR** (neat): $\nu_{\max}$ 2360, 2338, 1565, 1501, 1422, 1357, 1299, 1264, 1223, 1173, 1141, 1065, 822, 792, 729, 700 cm^{-1} ; **^1H NMR** (600 MHz, CDCl_3) δ 8.63 (d, J = 9.3 Hz, 1H), 8.52 (dd, J = 6.2, 1.1 Hz, 1H), 8.04 (s, 1H), 7.83 (dd, J = 9.3, 1.9 Hz, 1H), 7.64 (d, J = 8.5 Hz, 1H),

7.33 (dd, $J = 8.4, 6.1$ Hz, 1H); ^{13}C NMR (151 MHz, CDCl_3) δ 140.6, 135.9, 133.9, 131.8, 130.3, 124.7, 123.4, 122.4, 121.9; HRMS (ESI-TOF) calcd for $\text{C}_9\text{H}_6\text{BrNOH}^+ [(M+H)^+]$ 223.9711, found 223.9699.



4-Methoxyisoquinoline *N*-oxide (SI-6)


Using 4-methoxyisoquinoline in accordance with General Procedure I, the title compound was obtained (76% yield) as a white solid. **Mp**: 176 °C (CH_2Cl_2); $R_f = 0.19$ (CH_2Cl_2 :MeOH 20:1); **IR** (neat): ν_{max} 2360, 2340, 1395, 1339, 1171, 1138, 1089, 978, 864, 771, 669, 656 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3) δ 8.45 (d, $J = 1.5$ Hz, 1H), 8.08 (d, $J = 7.9$ Hz, 1H), 7.76 (d, $J = 1.4$ Hz, 1H), 7.66 (d, $J = 8.1$ Hz, 1H), 7.61 (ddd, $J = 8.2, 6.9, 1.2$ Hz, 1H), 7.56 (ddd, $J = 8.2, 6.8, 1.3$ Hz, 1H), 4.01 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.7, 130.1, 130.0, 128.4, 124.8, 123.1, 121.8, 119.4, 56.7; HRMS (ESI-TOF) calcd for $\text{C}_{10}\text{H}_9\text{NO}_2\text{H}^+ [(M+H)^+]$ 176.0706, found 176.0710.



5-Methoxyisoquinoline *N*-oxide (SI-7)


Using 5-methoxyisoquinoline in accordance with General Procedure I, the title compound was obtained (93% yield) as a white solid. **Mp**: 148 °C (CH_2Cl_2); $R_f = 0.22$ (CH_2Cl_2 :MeOH 20:1); **IR** (neat): ν_{max} 2359, 2340, 1628, 1596, 1468, 1440, 1389, 1323, 1273, 1250, 1206, 1193, 1157, 1103, 994, 960, 782, 730 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.70 (d, $J = 1.3$ Hz, 1H), 8.10 (dd, $J = 7.3, 1.7$ Hz, 1H), 8.04 (d, $J = 7.2$ Hz, 1H), 7.52 (t, $J = 8.1$ Hz, 1H), 7.27 (d, $J = 8.3$ Hz, 1H), 6.91 (d, $J = 7.8$ Hz, 1H), 4.01 (s, 3H); ^{13}C NMR (151

MHz, CDCl₃) δ 154.9, 136.1, 135.8, 130.8, 130.4, 121.1, 119.5, 116.9, 116.9, 107.1, 55.9;
HRMS (ESI-TOF) calcd for C₁₀H₉NO₂H⁺ [(M+H)⁺] 176.0706, found 176.0710.




4-Fluoroisoquinoline *N*-oxide (SI-8)

Using 4-fluoroisoquinoline in accordance with General Procedure I, the title compound was obtained (88% yield) as a white solid. **Mp**: 164 °C (CH₂Cl₂); **R_f** = 0.22 (CH₂Cl₂:MeOH 20:1); **IR** (neat): ν_{max} 2361, 2340, 1601, 1402, 1331, 1156, 1126, 1081, 773 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.62 (s, 1H), 8.11 (dd, *J* = 5.3, 1.5 Hz, 1H), 7.99 (d, *J* = 8.1 Hz, 1H), 7.74 (d, *J* = 8.1 Hz, 1H), 7.68 (dd, *J* = 7.6, 7.6 Hz, 1H), 7.65 (dd, *J* = 7.5, 7.5 Hz, 1H); **¹³C NMR** (151 MHz, CDCl₃) δ 156.7, 133.3, 130.9, 129.6, 129.3, 124.9, 124.8, 121.0, 120.4; **¹⁹F NMR** (376 MHz, CDCl₃) δ -132.91; **HRMS** (ESI-TOF) calcd for C₉H₆FNOH⁺ [(M+H)⁺] 164.0506, found 164.0503.



4-Chloroisoquinoline *N*-oxide (SI-9)

Using 4-chloroisoquinoline in accordance with General Procedure I, the title compound was obtained (88% yield) as a white solid. **Mp**: 174 °C (CH₂Cl₂); **R_f** = 0.22 (CH₂Cl₂:MeOH 20:1); **IR** (neat): ν_{max} 2361, 2341, 1621, 1590, 1555, 1487, 1373, 1327, 1225, 1175, 1129, 951, 762, 741, 644 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 8.69 (s, 1H), 8.29 (d, *J* = 1.7 Hz, 1H), 8.19 – 8.09 (m, 1H), 7.78 – 7.64 (m, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 136.0, 135.3, 130.9, 130.6, 129.9, 129.5, 127.4, 125.4, 123.9; **HRMS** (ESI-TOF) calcd for C₉H₆ClNOH⁺ [(M+H)⁺] 180.0211, found 180.0215.




6-Acetylfuro[3,2-b]pyridine 4-oxide (SI-10)

Using 1-(furo[3,2-b]pyridin-6-yl)ethanone in accordance with General Procedure I, the title compound was obtained (99% yield) as an off-white solid. **Mp**: 182 °C (CH₂Cl₂); **IR** (neat): $\nu_{\max}$ 2361, 2340, 1692, 1613, 1511, 1395, 1370, 1351, 1323, 1220, 1072, 878, 780, 616 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.78 (s, 1H), 7.99 (s, 1H), 7.91 (d, *J* = 2.3 Hz, 1H), 7.28 (d, *J* = 2.1 Hz, 1H), 2.64 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 193.6, 150.9, 150.4, 141.1, 135.5, 130.9, 110.3, 103.3, 27.1; **HRMS** (ESI-TOF) calcd for C₉H₇NO₃H⁺ [(M+H)⁺] 178.0499, found 178.0506.



N1-1,10-phenanthroline-N-oxide (SI-11)

Using 1,10-phenanthroline, the title compound was prepared according to a literature procedure¹. Spectroscopic data was identical to that previously reported.²




Quinine N-oxide (SI-12)

Using quinine, **SI-12** was prepared in accordance with a literature procedure³, and the title compound was obtained (78 % yield) as an off-white solid. **Mp**: 103-107 °C (CH₂Cl₂); **IR** (neat): $\nu_{\max}$ cm⁻¹ 3075, 2921, 1615, 1570, 1430, 1250, 1194, 1165, 1021, 825; **¹H NMR**

(400 MHz, CDCl₃) δ 8.43 (d, J = 9.5 Hz, 1H), 7.88 (d, J = 6.3 Hz, 1H), 7.22 - 7.10 (m, 2H), 6.93 (d, J = 2.6 Hz, 1H), 5.74 (ddd, J = 17.5, 10.3, 7.5 Hz, 1H), 5.03 - 4.79 (m, 2H), 3.87 (s, 3H), 3.08 (dd, J = 13.6, 10.1 Hz, 1H), 2.99 - 2.82 (m, 1H), 2.68-2.59 (m, 2H), 2.29 (s, 1H), 1.88 - 1.71 (m, 4H), 1.67 - 1.56 (m, 1H), 1.54-1.46 (m, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 159.8, 142.4, 136.1, 136.0, 134.5, 129.4, 123.6, 121.9, 119.3, 115.4, 102.6, 71.5, 61.1, 57.6, 56.8, 43.9, 40.6, 28.6, 28.2, 22.9; HRMS (ESI-TOF) calcd for C₂₀H₂₄N₂O₃H⁺ [(M+H)⁺] 341.1860, found 341.1864

General Procedure II: Protection and oxidation of azaindoles

To a mixture of the appropriate azaindole and K₂CO₃ (1.5 equiv) in MeCN (10 mL/g) was added benzenesulfonyl chloride (0.95 equiv.) drop-wise while maintaining the internal temperature below 25 °C. After the addition, the heterogeneous mixture was further agitated at room temperature until the *N*1- protection reached completion (about 1 hour). The crude reaction mixture was concentrated under reduced pressure. Ethyl acetate (10 mL/g) was added, followed by water (20 mL/g). The layers were separated, and the organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude solid was subjected to the oxidation step without further purification. The crude solid was dissolved in DCM (25 mL/g). To the solution was added aqueous hydrogen peroxide (35 wt%, 2.0 equiv) and MTO (2 mol%). The resulting mixture was further stirred at room temperature until *N*-oxide formation was complete (6 to 12 hours). Excess of hydrogen peroxide was quenched by slow addition of sat. NaHSO₃ solution (5 mL/g). The crude mixture was agitated for 30 minutes before layers were separated. The aqueous layer was tested for residue peroxide before discarded. The organic layer was dried over sodium sulfate, filtered and swapped into methyl *t*-butyl ether (20 mL/g). The resulting white slurry was filtered, and the cake was dried in vacuum oven to provide *N*1-benzenesulfonyl-azaindole *N*-oxides without further purification.




N1-benzenesulfonyl-4-methoxy-6-azainole N6-oxide (SI-13)

Using *N*1-benzenesulfonyl-4-methoxy-6-azainole in accordance with General Procedure II, the title compound was obtained (83% yield) as an off-white solid. **Mp**: 145 °C (CH₂Cl₂); **IR** (neat): ν_{max} 1578, 1491, 1445, 1424, 1188, 1158, 1116, 1088, 1067, 980, 840, 725, 685, 628 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 8.82 – 8.65 (m, 1H), 7.97 – 7.84 (m, 2H), 7.78 (s, 1H), 7.66 – 7.59 (m, 1H), 7.58 (dd, *J* = 3.6, 0.9 Hz, 1H), 7.55 – 7.48 (m, 2H), 6.73 (d, *J* = 3.6 Hz, 1H), 3.90 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 150.2, 137.4, 134.9, 132.0, 129.9, 128.4, 127.2, 120.9, 120.4, 119.9, 105.9, 56.7; **HRMS** (ESI-TOF) calcd for C₁₄H₁₂N₂O₄SH⁺ [(M+H)⁺] 305.0517, found 305.0595.

General Procedure III: Bromination of azine N-oxides


To a mixture of tetrabutylammonium bromide (1.5 equiv), 4 Å molecular sieves and the appropriate azine *N*-oxide is added CH₂Cl₂ (0.01M) and the mixture is stirred at room temperature for 10 min. *p*-Toluenesulfonic anhydride (1.5 equiv) is added and the reaction is stirred at room temperature overnight. The reaction mixture is filtrated and concentrated under reduced pressure. The crude product is purified by flash column chromatography using hexanes/CH₂Cl₂ and hexanes/EtOAc solvent mixtures.



2-Bromoquinoline (15)


Using quinoline *N*-oxide, in accordance with General Procedure III, the title compound was obtained (35% yield) as a white solid. The spectroscopic data were consistent with those of a commercial sample. **¹H NMR** (150 MHz, CDCl₃) δ 8.02 (d, *J*=9.0 Hz, 1H), 7.97 (d, *J*=8.4 Hz, 1H), 7.79 (d, *J*= 7.8 Hz, 1H), 7.73–7.71 (m, 1H), 7.57–7.55 (m, 1H), 7.50 (d,

$J=8.4$ Hz, 1H); ^{13}C NMR (151 MHz, CDCl_3) δ 148.7, 141.9, 138.5, 130.7, 127.8, 127.1, 125.9;




2-Bromo-3-methoxyquinoline (16)

Using 3-methoxyquinoline *N*-oxide (**11**) in accordance with General Procedure III, the title compound was obtained (63% yield) as a white solid. **Mp**: 58 °C (CH_2Cl_2); R_f = 0.36 (hexanes:EtOAc 7:1); **IR** (neat): ν_{max} 2360, 2334, 1588, 1404, 1348, 1222 1199, 1051, 772, 748 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3) δ 7.99 (dd, J = 8.2, 0.7 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.57 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.53 (ddd, J = 8.2, 7.0, 1.4 Hz, 1H), 7.36 (d, J = 1.5 Hz, 1H), 4.02 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 150.0, 143.3, 136.4, 128.7, 128.5, 127.8, 127.7, 126.5, 113.5, 56.5; **HRMS** (ESI-TOF) calcd for $\text{C}_{10}\text{H}_8\text{BrNOH}^+$ [(M+H) $^+$] 237.9862, found 237.9863.




2-Bromo-4-methoxyquinoline (17)

Using 4-methoxyquinoline *N*-oxide (**SI-1**) in accordance with General Procedure III, the title compound was obtained (42% yield) as a white solid. R_f = 0.35 (hexanes:EtOAc 5:1); **Mp**: 75 °C (CH_2Cl_2); **IR** (neat): ν_{max} 2360, 2340, 1563, 1507, 1458, 1412, 131, 1260, 1110, 1092, 1019, 987, 880, 764, 730 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3) δ 8.14 (dd, J = 8.3, 1.6 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.70 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.55 – 7.49 (m, 2H), 6.88 (s, 1H), 4.06 (d, J = 1.2 Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 163.2, 148.9, 142.6, 130.9, 128.3, 126.3, 122.2, 120.7, 104.8, 56.3; **HRMS** (ESI-TOF) calcd for $\text{C}_{10}\text{H}_8\text{BrNOH}^+$ [(M+H) $^+$] 237.9789, found 237.9866.




2-Bromo-5-methoxyquinoline (18)

Using 5-methoxyquinoline *N*-oxide (**SI-2**) in accordance with General Procedure III, the title compound was obtained (55% yield) as a white solid. R_f = 0.30 (hexanes:EtOAc 5:1); **Mp**: 58-60 °C (CH₂Cl₂); **IR** (neat): $\nu_{\max}$ 2360, 2340, 1563, 1507, 1458, 1412, 131, 1260, 1110, 1092, 1019, 987, 880, 764, 730 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.40 (d, J = 8.7, 1H), 7.63-7.62 (m, 2H), 7.49 (d, J = 8.7 Hz, 1H), 6.89 (dd, J = 6.2, 2.5 Hz, 1H), 4.01 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 155.5, 149.6, 142.6, 133.6, 130.9, 124.8, 120.8, 119.7, 105.1, 56.0; **HRMS** (ESI-TOF) calcd for C₁₀H₈BrNOH⁺ [(M+H)⁺] 237.9789, found 237.9866.




2-Bromo-6-methoxyquinoline (9)

Using 6-methoxyquinoline *N*-oxide (**8**) in accordance with General Procedure III, the title compound was obtained (97% yield) as a white solid. For the large-scale reaction setup (1.05 g, 6.00 mmol) the reaction was scaled up according to General Procedure II and the product was obtained (70%) as a white solid. **Mp**: 110 °C (CH₂Cl₂); R_f = 0.52 (hexanes:EtOAc 5:1); **IR** (neat): $\nu_{\max}$ 2360, 2340, 1618, 1562, 1494, 1452, 1376, 1337, 1229, 1292, 1090, 1025, 910, 838, 802, 669 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 7.86 (d, J = 9.2 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.37 (d, J = 8.6 Hz, 1H), 7.30 (d, J = 7.5 Hz, 1H), 6.96 (s, 1H), 3.86 (s, 3H); **¹³C NMR** (126 MHz, CDCl₃) δ 158.1, 144.6, 138.8, 137.2, 129.9, 128.1, 125.8, 123.1, 105.3, 55.6; **HRMS** (ESI-TOF) calcd for C₁₀H₈BrNOH⁺ [(M+H)⁺] 237.9862, found 237.9854.




2-Bromo-8-methoxyquinoline (19)

Using 8-methoxyquinoline *N*-oxide (**SI-3**) in accordance with General Procedure III, the title compound was obtained (71% yield) as an orange-colored solid. **Mp**: 72 °C. **R_f** = 0.30 (hexanes:EtOAc 5:1); **IR** (neat): $\nu_{\max}$ 2361, 2338, 1584, 1562, 1492, 1465, 1416, 1374, 1322, 1299, 1261, 1112, 1095, 991, 828, 751, 713 cm^{-1} ; **¹H NMR** (600 MHz, CDCl₃) δ 7.95 (d, *J* = 8.5 Hz, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.49 (dd, *J* = 7.9, 7.9 Hz, 1H), 7.36 (dd, *J* = 8.1, 1.2 Hz, 1H), 7.08 (dd, *J* = 7.8, 1.1 Hz, 1H), 4.06 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 154.8, 141.0, 140.4, 138.4, 128.3, 127.5, 126.7, 119.4, 108.9, 56.2; **HRMS** (ESI-TOF) calcd for C₁₀H₈BrNOH⁺ [(M+H)⁺] 237.9862, found 237.9859.




2-Bromo-6-fluoroquinoline (20)

Using 6-fluoroquinoline *N*-oxide (**10**) in accordance with General Procedure III, the title compound was obtained (71% yield) as a white solid. **Mp**: 128 °C (CH₂Cl₂); **R_f** = 0.53 (hexanes:EtOAc 7:1); **IR** (neat): $\nu_{\max}$ 2360, 2340, 1580, 1563, 1485, 1442, 1330, 1282, 1129, 1083, 874, 825, 811 cm^{-1} ; **¹H NMR** (500 MHz, CDCl₃) δ 7.99 (dd, *J* = 9.2, 5.2 Hz, 1H), 7.89 (d, *J* = 8.6 Hz, 1H), 7.49 (s, 1H), 7.45 (dd, *J* = 8.8, 2.5 Hz, 1H), 7.37 (dd, *J* = 8.5, 2.8 Hz, 1H); **¹³C NMR** (126 MHz, CDCl₃) δ 160.6, 145.6, 141.1, 137.7, 131.2, 127.0, 126.6, 120.7, 111.1; **HRMS** (ESI-TOF) calcd for C₉H₅BrFNH⁺ [(M+H)⁺] 225.9662, found 225.9662.




2-Bromo-6-chloroquinoline (21)

Using 6-chloroquinoline *N*-oxide (**SI-4**) in accordance with General Procedure III, the title compound was obtained (58% yield) as a white solid. **Mp**: 128 °C (CH₂Cl₂); **R_f** = 0.53 (hexanes:EtOAc 7:1); **IR** (neat): ν_{max} 2361, 2339, 1580, 1486, 1282, 1129, 1083, 875, 825, 671, 653 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 7.92 (d, *J* = 9.0 Hz, 1H), 7.85 (d, *J* = 8.6 Hz, 1H), 7.72 (d, *J* = 2.3 Hz, 1H), 7.62 (dd, *J* = 9.0, 2.4 Hz, 1H), 7.49 (d, *J* = 8.6 Hz, 1H); **¹³C NMR** (126 MHz, CDCl₃) δ 146.9, 142.2, 137.3, 132.9, 131.5, 130.3, 127.6, 126.8, 126.5; **HRMS** (ESI-TOF) calcd for C₉H₅BrClNH⁺ [(M+H)⁺] 241.9367, found 241.9367.




2,6-Dibromoquinoline (22)

Using 6-bromoquinoline *N*-oxide (**SI-5**) in accordance with General Procedure III, the title compound was obtained (63% yield) as a white solid. **Mp**: 151 °C (CH₂Cl₂); **R_f** = 0.53 (hexanes:EtOAc 7:1); **IR** (neat): ν_{max} 2361, 2338, 1576, 1543, 1480, 1439, 1327, 1279, 1127, 1082, 589, 821, 671 cm⁻¹; **¹H NMR** (125 MHz, CDCl₃) δ 7.97 (d, *J* = 2.2 Hz, 1H), 7.93 – 7.87 (m, 2H), 7.80 (dd, *J* = 8.9, 2.1 Hz, 1H), 7.54 (d, *J* = 8.5 Hz, 1H); **¹³C NMR** (151 MHz, CDCl₃) δ 147.3, 142.4, 137.4, 134.2, 130.5, 129.9, 128.2, 126.9, 121.1; **HRMS** (ESI-TOF) calcd for C₉H₅Br₂NH⁺ [(M+H)⁺] 285.8861, found 285.8858.




1-Bromoisoquinoline (23)

Using isoquinoline *N*-oxide in accordance with General Procedure III, the title compound was obtained (55% yield) as a white solid. All spectroscopic data were consistent with a commercial sample. **¹H NMR** (100 MHz, CDCl₃) δ 8.31 (d, *J* = 8.0 Hz, 1H), 8.27 (d, *J* = 5.6 Hz, 1H), 7.83 (d, *J* = 10.0 Hz, 1H), 7.73 – 7.68 (m, 2H), 7.62 (d, *J* = 6.8 Hz, 1H); **¹³C NMR** (151 MHz, CDCl₃) δ 145.2, 141.8, 137.6, 131.6, 129.1, 128.9, 127.2, 121.4.




1-Bromo-4-methoxyisoquinoline (24)

Using 4-methoxyisoquinoline *N*-oxide (**SI-1**) in accordance with General Procedure III, the title compound was obtained (97% yield) as a white solid. **Mp**: 70 °C (CH₂Cl₂); **R_f** = 0.27 (hexanes:EtOAc 7:1); **IR** (neat): ν_{max} 2361, 2340, 1580, 1556, 1503, 1454, 1315, 1278, 1099, 989, 929, 876, 756, 623, 606 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 8.20 (dd, *J* = 9.2, 9.2 Hz, 2H), 7.81 (s, 1H), 7.76 – 7.66 (m, 2H), 4.05 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 150.9, 135.6, 130.4, 130.2, 129.1, 128.9, 128.3, 122.2, 121.9, 56.3; **HRMS** (ESI-TOF) calcd for C₁₀H₈BrNOH⁺ [(M+H)⁺] 237.9862, found 237.9877.




1-Bromo-5-methoxyisoquinoline (25)

Using 5-methoxyisoquinoline *N*-oxide (**SI-2**) in accordance with General Procedure III, the title compound was obtained (50% yield) as a white solid. **Mp**: 113 °C (CH₂Cl₂); **R_f** = 0.40 (hexanes:EtOAc 7:1); **IR** (neat): ν_{max} 2359, 2339, 1579, 1487, 1461, 1376, 1327, 1317, 1264, 1005, 834, 789, 773, 740 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.14 (d, *J* = 5.7 Hz, 1H), 7.91 (d, *J* = 5.7 Hz, 1H), 7.75 (d, *J* = 8.6 Hz, 1H), 7.49 (dd, *J* = 8.6, 7.8 Hz, 1H), 6.95 (dd, *J* = 7.8, 0.9 Hz, 1H), 3.92 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 154.8, 144.9, 141.7, 130.2, 129.8, 128.8, 120.4, 115.8, 108.5, 56.1; **HRMS** (ESI-TOF) calcd for C₁₀H₈BrNOH⁺ [(M+H)⁺] 237.9862, found 237.9865.




1-Bromo-4-fluoroisoquinoline (26)

Using 4-fluoroisoquinoline *N*-oxide (**SI-8**) in accordance with General Procedure III, the title compound was obtained (87% yield) as a white solid. **Mp**: 62 °C (CH₂Cl₂); **R_f** = 0.60 (hexanes:EtOAc 7:1); **IR** (neat): ν_{max} 2361, 2338, 1592, 1504, 1417, 1378, 1310, 1261, 1068, 948, 880, 762, 670 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.24 (d, *J* = 9.0 Hz, 1H), 8.14 (s, 1H), 8.06 (d, *J* = 8.3 Hz, 1H), 7.81 (dd, *J* = 8.5, 7.0 Hz, 1H), 7.74 (dd, *J* = 8.5, 7.0 Hz, 1H); **¹³C NMR** (600 MHz, CDCl₃) δ 155.31, 138.8, 131.6, 129.8, 128.6, 128.3, 127.6, 127.5, 120.4; **¹⁹F NMR** (376 MHz, CDCl₃) δ -140.34; **HRMS** (ESI-TOF) calcd for C₉H₂BrNFH⁺ [(M+H)⁺] 225.9662, found 225.9663.




1-Bromo-4-chloroisoquinoline (27)

Using 4-chloroisoquinoline *N*-oxide (**SI-9**) in accordance with General Procedure III, the title compound was obtained (85% yield) as a white solid. **Mp**: 72 °C (CH₂Cl₂); **R_f** = 0.63 (hexanes:EtOAc 7:1); **IR** (neat): ν_{max} 2361, 2340, 1563, 1316, 1293, 1217, 980, 758, 678, 563 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.34 (s, 1H), 8.33 (d, *J* = 9.4 Hz, 1H), 8.22 (d, *J* = 8.1 Hz, 1H), 7.88 (ddd, *J* = 8.4, 7.0, 1.3 Hz, 1H), 7.78 (ddd, *J* = 8.3, 7.1, 1.3 Hz, 1H); **¹³C NMR** (151 MHz, CDCl₃) δ 143.67, 140.8, 135.0, 132.3, 129.8, 129.6, 129.3, 128.9, 124.3; **HRMS** (ESI-TOF) calcd for C₉H₅BrClNH⁺ [(M+H)⁺] 241.9367, found 241.9370.




N1-benzenesulfonyl-7-bromo-4-methoxy-6-azainole (28)

Using *N*1-benzenesulfonyl-4-methoxy-6-azainole *N*6-oxide (**SI-10**) in accordance with General Procedure III, the title compound was obtained (65% yield) as a white solid. **Mp**: 122 °C (CH₂Cl₂); **R_f** = (CH₂Cl₂:MeOH 20:1); **IR** (neat): $\nu_{\max}$ 2360, 2340, 1513, 1453, 1360, 1290, 1174, 1116, 927, 753, 726, 684, 614, 593, 570 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 7.99 (d, *J* = 3.8 Hz, 1H), 7.82 (dd, *J* = 8.5, 1.3 Hz, 2H), 7.67 – 7.57 (m, 1H), 7.51 (dd, *J* = 8.4, 7.2 Hz, 2H), 6.87 (d, *J* = 3.8 Hz, 1H), 3.99 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 149.4, 139.8, 134.2, 132.4, 131.4, 129.5, 127.4, 123.8, 116.0, 103.9, 99.7, 56.5; **HRMS** (ESI-TOF) calcd for C₁₄H₁₁BrN₂O₃SH⁺ [(M+H)⁺] 366.9674, found 366.9747.




1-(5-bromofuro[3,2-b]pyridin-6-yl)ethanone (29)

Using 6-acetylfuro[3,2-b]pyridine 4-oxide (**SI-11**) in accordance with General Procedure III, the title compound was obtained (92% yield) as a white solid. **Mp**: 35 °C (CH₂Cl₂); **R_f** = 0.28 (hexanes:EtOAc 7:1); **IR** (neat): $\nu_{\max}$ 2361, 2340, 1697, 1610, 1367, 1318, 1280, 1220, 1119, 1101, 1022, 786, 750, 649 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 7.97 (d, *J* = 2.3 Hz, 1H), 7.90 (s, 1H), 7.31 – 7.20 (m, 1H), 6.99 (d, *J* = 2.3 Hz, 1H); **¹³C NMR** (151 MHz, CDCl₃) δ 199.6, 176.8, 152.5, 149.7, 146.6, 133.6, 133.4, 120.2, 108.0, 30.8; **HRMS** (ESI-TOF) calcd for C₉H₆BrNO₂H⁺ [(M+H)⁺] 239.9655, found 239.9664.



2-Bromo-1,10-phenanthroline (30)

Using 1,10-phenanthroline *N*-oxide (**SI-11**) in accordance with General Procedure III, the title compound was obtained (70% yield) as a white solid. **Mp**: °C (CH₂Cl₂); **R_f** = (CH₂Cl₂:MeOH 20:1); **IR** (neat): $\nu_{\max}$ cm⁻¹ 3041, 2921, 1576, 1486, 1379, 1060, 1032, 840, 724; **¹H NMR** (400 MHz, CDCl₃) δ 9.21 (dd, *J* = 4.3, 1.8 Hz, 1H), 8.24 (dd, *J* = 8.1, 1.8 Hz, 1H), 8.06 (d, *J* = 8.4 Hz, 1H), 7.81 (d, *J* = 8.8 Hz, 1H), 7.78 – 7.72 (m, 2H), 7.64 (dd, *J* = 8.1, 4.3 Hz, 1H); **¹³C NMR** (151 MHz, CDCl₃) δ 150.9, 146.7, 145.0, 142.7, 138.3, 136.3, 129.1, 128.1, 127.6, 127.2, 126.0, 123.6; **HRMS** (ESI-TOF) calcd for C₁₂H₇BrN₂H⁺ [(M+H)⁺] 258.9793, found 258.9871.




2-Bromoquinine (31)

To a mixture of quinine *N*-oxide (**SI-12**), tetrabutylammonium bromide (4.0 equiv), and 4 Å molecular sieves is added CH₂Cl₂ (0.01M) and the mixture is stirred at room temperature for 10 min. *p*-Toluenesulfonic anhydride (2.0 equiv) is added and the reaction is stirred at room temperature overnight. The reaction mixture is filtrated, the organic layer washed twice with LiCl (sat. aq.), dried over MgSO₄ and concentrated under reduced pressure. The crude product is purified by flash column chromatography using a gradient of DCM to 10% MeOH/DCM to give the title compound (63%) as a white solid. **Mp**: 125-130°C (CH₂Cl₂); **R_f** =0.4 (CH₂Cl₂:MeOH 10:1); **IR** (neat): $\nu_{\max}$ cm⁻¹ 3254, 2923, 2549, 1618, 1503, 1286, 1233, 1092, 1024, 896, 830, 726; **¹H NMR** (100 MHz, CDCl₃) δ 7.74 (s, 1H), 7.58 (d, *J* = 9.2 Hz, 1H), 7.02 (dd, *J* = 9.2, 2.6 Hz, 1H), 6.84 (d, *J* = 2.7 Hz, 1H), 6.39 (s, 1H), 5.53 (ddd, *J* = 17.2, 10.5, 6.7 Hz, 1H), 5.05 – 4.91 (m, 2H), 4.50 (s, 1H), 3.76 (s, 3H), 3.41 (dd, *J* = 13.6, 10.7 Hz, 1H), 3.38 – 3.33 (m, 1H), 3.31 – 3.24 (m, 1H), 3.10 (td, *J* = 11.9, 5.3 Hz, 1H), 3.03 (ddd, *J* = 13.7, 5.3, 2.7 Hz, 1H), 2.68 (s, 1H), 2.26 –

2.17 (m, 1H), 2.10 – 2.02 (m, 2H), 1.88 – 1.80 (m, 1H), 1.70-1.64 (m, 1H); ^{13}C NMR (CDCl_3 , 151 MHz) δ 159.4, 147.5, 144.9, 139.5, 138.0, 131.5, 124.9, 124.2, 123.7, 118.2, 100.9, 66.7, 60.8, 58.3, 55.8, 45.2, 38.0, 27.7, 25.1, 25.1, 20.6. HRMS (ESI-TOF) calcd for $\text{C}_{20}\text{H}_{23}\text{BrN}_2\text{O}_2\text{H}^+$ [(M+H) $^+$] 403.1016, found 403.1011.


Procedure for chlorination of 6-methoxyquinoline *N*-oxide (8)

A solution of 6-methoxyquinoline *N*-oxide (18 mg, 0.10 mmol, 1.00 equiv) and tetrabutylammonium chloride hydrate (42 mg, 0.15 mmol, 1.50 equiv) and 4 Å molecular sieves in CH_2Cl_2 (10 mL) was stirred at room temperature for 10 min, then *p*-toluenesulfonic anhydride (49 mg, 0.15 mmol, 1.50 equiv) was added and the mixture was stirred at room temperature overnight. The solution was filtered and the solvent was evaporated. The crude reaction mixture was purified by flash column chromatography using hexanes/EtOAc as the solvent mixture. The two regioisomers (**C2:C4** 10:1) were obtained as white solids.



2-Chloro-6-methoxyquinoline (**14**)


The title compound was obtained (87% yield) as a white solid. Mp: 86 °C (CH_2Cl_2); R_f = 0.47 (hexanes:EtOAc 5:1); IR (neat): ν_{max} 2361, 2340, 1622, 1584, 1496, 1470, 1376, 1342, 1295, 1244, 1230, 1161, 1127, 1092, 1018, 954, 918, 849, 824, 799 cm^{-1} ; ^1H NMR (600 MHz, CDCl_3) δ 7.95 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 9.2 Hz, 1H), 7.35 (dd, J = 9.2, 2.8 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 7.03 (d, J = 2.8 Hz, 1H), 3.89 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 158.1, 148.1, 143.8, 137.7, 129.9, 127.9, 123.1, 122.5, 105.3, 55.7; HRMS (ESI-TOF) calcd for $\text{C}_{10}\text{H}_8\text{ClNO}^+$ [(M+H) $^+$] 194.0367, found 194.0374.



4-Chloro-6-methoxyquinoline (SI-14)


The title compound was obtained (9% yield) as a white solid. Mp: 51 °C (CH₂Cl₂); **R_f** = 0.37 (hexanes:EtOAc 5:1); **IR** (neat): ν_{max} 2361, 2340, 1621, 1579, 1497, 1424, 1295, 1264, 1193, 1162, 1064, 1032, 848, 826, 717, 673 cm⁻¹; **¹H NMR** (600 MHz, CDCl₃) δ 8.63 (d, *J* = 4.7 Hz, 1H), 8.01 (d, *J* = 9.1 Hz, 1H), 7.46 (d, *J* = 4.7 Hz, 1H), 7.44 (d, *J* = 2.8 Hz, 1H), 7.41 (dd, *J* = 9.1, 2.8 Hz, 1H), 3.98 (s, 3H); **¹³C NMR** (151 MHz, CDCl₃) δ 158.9, 147.4, 145.4, 141.1, 131.5, 127.7, 123.5, 121.6, 101.7, 55.9; **HRMS** (ESI-TOF) calcd for C₁₀H₈ClNO⁺ [(M+H)⁺] 194.0367, found 194.0376.

Procedure for One-Pot Oxidation/Bromination Sequence



To a solution of 6-methoxyquinoline (28 μ L, 0.200 mmol) in DCM (0.2 mL) was added UHP (37.6 mg, 0.400 mmol) and MTO (4 mg, 0.016 mmol) and the mixture capped and stirred 24 h. At this time the mixture was diluted to 20 mL with DCM and molecular sieves were added. After stirring 5 min, TBABr (96.5 mg, 0.300 mmol) followed by Ts₂O (98 mg, 0.300 mmol) were added and the mixture stirred 12 h. The mixture was then filtered, quenched with 1M NaOH, the aqueous layer extracted twice with DCM, the combined organic extracts dried over Mg₂SO₄ and concentrated to yield a yellow oil. Silica gel chromatography (1:10 EtOAc:Hex) yielded **9** as a white solid (34 mg, 70%).

Table of Pyridines Screened in Attempted Bromination



References

1. Sun, W. H.; He, S. Y.; Zhang, S.; Zhang, W.; Song, Y. X.; Ma, H. W. *Organomet.* **2006**, 25 (3), 666-677.
2. Engel, Y.; Dahan, A.; Rozenshine-Kemelmakher, E.; Gozin, M. *J. Org. Chem.* **2007**, 72 (7), 2318-2328.
3. Wu, Y. W.; Singh, R. P.; Deng, L. *J. Am. Chem. Soc.* **2011**, 133 (32), 12458-12461.

Regioselective Bromination of Fused Heterocyclic *N*-Oxides

Sarah E. Wengryniuk, Andreas Weickgenannt, Christopher Reiher, Neil Strotman, Ke
Chen*, Martin D. Eastgate*, Phil S. Baran*

Department of Chemistry and Chemical Biology, The Scripps Research Institute, 10550

North Torrey Pines Road, San Diego, CA 92037, USA

Chemical Development, Bristol-Myers Squibb, One Squibb Drive, New Brunswick, New

Jersey, 08903, United States

Spectral File

